The duration of diabetes influences the development of CAD in patients with type 1 diabetes, but such a relationship has not been demonstrated in those with type 2. Therefore, it is unclear whether the duration of asymptomatic hyperglyce-mia, or the state of impaired glucose tolerance, may have an important role on the development of CAD preceding the overt manifestations of type 2 diabetes (31,32). Several studies have shown that the mortality rate due to CAD was higher in patients with impaired glucose tolerance compared to normoglycemic men, although it was smaller when compared to that of patients with overt diabetes. At least one study has demonstrated that the risk of CAD increases linearly with fasting blood glucose levels in patients with impaired glucose tolerance, whereas the fasting insulin level has been implicated as a possible independent risk factor for CAD mortality in another study. Early impairment of LV diastolic function has been documented not only in patients with type 2 diabetes, but also in those with impaired glucose tolerance, independent of the confounding role of myocar-dial ischemia, body weight, and levels of arterial blood pressure (33). Similarly, early atherosclerotic changes, as well as borderline impairment of cardiac auto-nomic function, could be demonstrated in those subjects with impaired glucose tolerance. The various diagnostic tests previously reviewed that are useful in the diagnosis of heart disease in patients with previously diagnosed diabetes can also be applied to those with impaired glucose tolerance or prediabetic states, although the clinical benefits and cost effectiveness of a strategy directed to screen for early cardiac abnormalities in asymptomatic subjects with prediabetic states or impaired glucose tolerance remains to be established.
1. Wingard D, Barrett-Conor E. Heart disease and diabetes. In: Harris MI, eds. Diabetes |-*„ in America. Bethesda, MD: NIH publication No. 95-1468, 1995:429-448. J
2. Kleinman JC, Donahue RP, Harris MI, Finucane FF, Madans JH, Brock DB. Q
Mortality among diabetics in a national sample. Am J Epidemiol 1988; 128:389401.
3. Bloomgarden ZT. American Diabetes Association 60th Scientific Sessions, 2000 Cardiovascular disease in diabetes. Diabetes Care 2001; 24:399-404.
4. Garcia MJ, McNamara PM, Gordon T, Kannel WB. Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study. Diabetes 1974; 23:105-111.
6. Kannel WB. Silent myocardial ischemia and infarction: insights from the Framing-ham Study. Cardiol Clin 1986; 4:583-591.
7. Paillole C, Passa P, Paycha F, Juliard JM, Steg PG, Leblanc H, Philippe L, Gourgon R. Non-invasive identification of severe coronary artery disease in patients with long-standing diabetes mellitus. Eur J Med 1992; 1:464-468.
8. Gibbons RJ, Balady GJ, Beasley JW, Bricker JT, Duvernoy WF, Froelicher VF, Mark DB, Marwick TH, McCallister BD, Thompson PD, Jr., Winters WL, Yanowitz FG, Ritchie JL, Cheitlin MD, Eagle KA, Gardner TJ, Garson A, Jr., Lewis RP, O'Rourke RA, Ryan TJ. ACC/AHA Guidelines for Exercise Testing. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Exercise Testing). J Am Coll Cardiol 1997; 30: 260-311.
9. Stone PH, Chaitman BR, Forman S, Andrews TC, Bittner V, Bourassa MG, Davies RF, Deanfield JE, Frishman W, Goldberg AD, MacCallum G, Ouyang P, Pepine CJ, Pratt CM, Sharaf B, Steingart R, Knatterud GL, Sopko G, Conti CR. Prognostic significance of myocardial ischemia detected by ambulatory electrocardiography, exercise treadmill testing, and electrocardiogram at rest to predict cardiac events by one year (the Asymptomatic Cardiac Ischemia Pilot [ACIP] study). Am J Cardiol 1997; 80:1395-401.
10. Davies RF, Goldberg AD, Forman S, Pepine CJ, Knatterud GL, Geller N, Sopko G, Pratt C, Deanfield J, Conti CR. Asymptomatic Cardiac Ischemia Pilot (ACIP) study two-year follow-up: outcomes of patients randomized to initial strategies of medical therapy versus revascularization. Circulation 1997; 95:2037-2043.
11. Topol EJ, Nissen SE. Our preoccupation with coronary luminology. The dissociation between clinical and angiographic findings in ischemic heart disease. Circulation 1995; 92:2333-2342.
12. Riff ER, Riff KM. Abnormalities of myocardial depolarization in overt, subclinical and prediabetes. A vectorcardiographic study. Diabetes 1974; 23:572-578.
13. Schurgin S, Rich S, Mazzone T. Increased prevalence of significant coronary artery calcification in patients with diabetes. Diabetes Care 2001; 24:335-338.
14. LeWinter MM. Diabetic cardiomyopathy: an overview. Coron Artery Dis 1996; 7: 95-98.
15. Spector KS. Diabetic cardiomyopathy. Clin Cardiol 1998; 21:885-887.
16. Poirier P, Garneau C, Marois L, Jobin JF, Dumesnil JG. Impact of diastolic dysfunction on maximal treadmill performance in type 2 diabetic subjects without clinical heart disease. Med Sci Sports Exercise Med 1999; 31:S361. a
17. Vered A, Battler A, Segal P, Liberman D, Yerushalmi Y, Berezin M, Neufeld HN.
Was this article helpful?
When it comes to pieces of aerobic equipment to buy, treadmills continue to be the most popular and the most valuable. And why not? They are simple to use and naturally intuitive. They burn calories effectively and offer a wide range of exercise options, whether walking, climbing, or jogging.